Table I.

Partial list of inner ear diseases potentially amenable to intracochlear drug delivery, along with salient comments regarding the patient population and broad requirements for each condition.

Inner Ear Disease	Considerations for Drug Delivery
Sensorineural Hearing Loss	Largest patient population May require extended delivery of multiple compounds for regeneration
Noise-Induced Hearing Loss	Large and rapidly growing patient population May require timed-sequenced delivery High priority for Department of Defense
Sudden Sensorineural Hearing Loss	Rapid intervention required Therapeutics suitable for local delivery may already exist
Autoimmune Inner Ear Disease	Small patient population but urgent need Therapeutics suitable for local delivery may already exist
Menieres Disease	Relatively large patient population May require patient-controlled burst delivery
Tinnitus	Very large patient population with complex spectrum
Cisplatin Ototoxicity Protection	Very important for pediatric population Therapeutics suitable for local delivery may already exist Duration of delivery weeks to months
Radiation-Induced Ototoxicity Protection	Occurs in large percentage of patients with range of head and neck tumors Duration of delivery weeks to months
Cranial Nerve Schwannoma	Potential alternative to surgery May require extended delivery